PubMed Health⌕ Search

Biomedical subjects

H Arnberg

Publications and source records attributed to H Arnberg.

24 records · Page 2Linked to original sources
PubMed1989

Chromogranins--new sensitive markers for neuroendocrine tumors.

Chromogranins A, B and C, proteins that are costored and coreleased with peptides and amines, have been identified in a variety of endocrine and nervous tissues, both normal and neoplastic. We examined the secretion of chromogranin A and chromogranin A + B by hormone-producing tumors in patients with endocrine pancreatic tumors (EPT), carcinoid tumors, pheochromocytomas and small cell lung cancer (SCLC). Radioimmunoassay (RIA) of the plasma/serum concentrations of chromogranin A + B showed a greater sensitivity than RIA of chromogranin A alone. All patients with EPT, carcinoids and pheochromocytomas had increased levels of chromogranin A + B, whereas a small number of the patients (5/18 with EPT and 1/3 with pheochromocytomas) had normal levels of chromogranin A. Also in immunocytochemical stainings, our polyclonal antiserum detecting both chromogranin A and B showed a greater sensitivity than other available antisera against chromogranin A, B and C.

Adenoma, Islet Cell↗
PubMed1988

Radioimmunodetection of prostatic cancer with 125I-labelled antibody against prostatic specific antigen.

A murine monoclonal antibody directed against human prostatic specific antigen was labelled with 125I and used in immunoscintigraphy studies of nude mice bearing xenografts of a human prostatic carcinoma cell line (DU-145). The antibody was injected intraperitoneally and the distribution was followed daily with the use of a gamma scintillation camera. Specific uptake was seen in the tumor, with optimal imaging 7-9 days after the injection of the radio-labelled antibody. Fab fragments of the radio labelled antibody were also investigated. These exhibited a strikingly shorter bio-distribution time, with optimal visualization of the tumor after 14-28 hours. Normal murine IgG and Fab fragments used in control experiments exhibited radioactivity that was comparable to that of normal tissue.

Animals↗
PubMedDate not supplied

Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen.

Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPACyk) and with the established reference markers for these malignancies (CEA and NSE for lung, CA 15-3 for breast, CEA and CA 19-9 for colorectal tumors). Analysis of receiver operating characteristic (ROC) curves in lung, colorectal and bladder cancer showed similar sensitivities for the two assays, ranging from 50% to 80% with a specificity of 95%. In breast cancer all the markers studied showed poor sensitivity. However, TPA determination by either method could discriminate advanced stage (stages III and IV) from early stage disease (stages 0 to II). TPA showed similar discriminating ability in bladder cancer. On the basis of the results obtained in our patient series, it seems that of the cytokeratin markers studied, TPA and TPA-M are the most sensitive and offer a wide range of clinical applications.

Antibodies, Monoclonal↗
PubMedDate not supplied

GM-CSF in chemotherapy-induced febrile neutropenia--a double-blind randomized study.

Modern chemotherapy programmes render patients susceptible to bacterial and fungal infections, and the risk of developing febrile neutropenia after a chemotherapy course is in proportion to the severity and duration of the neutropenia thus caused. This double-blind randomized study presents details of 29 patients who developed febrile neutropenia an average of 10 days after their course of chemotherapy for different types and stages of malignancy. Fourteen received granulocyte/macrophage colony stimulating factor (GM-CSF) and 15 placebo during 7 consecutive days as subcutaneous injections. The GM-CSF group demonstrated significant increases in total white blood cell count (TWBC) and absolute neutrophil count (ANC) from the morning of the third day of the study. The study concludes that GM-CSF has an important therapeutic role in the treatment of febrile neutropenia that arises during intensive chemotherapy programmes but further studies of dosage and therapy duration are required, as is the development of methods of assessing bone marrow vitality.

Adult↗